Inspira Completes Clinical Study for HYLA(TM) Blood Sensor - Ahead of Regulatory Submission

Stock Information for Inspira Technologies Oxy B.H.N. Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inspira Technologies Oxy B.H.N. Ltd.

Inspira Technologies Announces Strategic Leap in Lab Capabilities - Accelerating Next-Generation Diagnostics and Blood Technology
Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion
Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira's Global Ecosystem
Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Inspira to Unveil HYLA(TM) Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed
Inspira Announces 97.3% Accuracy Results for HYLA(TM) Blood Sensor, Advancing Toward FDA Submission for Clearance

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.